Amylyx Pharmaceuticals (AMLX) Cash & Current Investments (2021 - 2025)
Historic Cash & Current Investments for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $344.0 million.
- Amylyx Pharmaceuticals' Cash & Current Investments rose 4675.65% to $344.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.0 million, marking a year-over-year increase of 4675.65%. This contributed to the annual value of $176.5 million for FY2024, which is 5247.2% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Cash & Current Investments of $344.0 million as of Q3 2025, which was up 4675.65% from $180.8 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Cash & Current Investments registered a high of $373.3 million during Q1 2024, and its lowest value of $96.1 million during Q4 2021.
- In the last 5 years, Amylyx Pharmaceuticals' Cash & Current Investments had a median value of $282.5 million in 2022 and averaged $270.0 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Cash & Current Investments soared by 26095.74% in 2022 and then plummeted by 5247.2% in 2024.
- Over the past 5 years, Amylyx Pharmaceuticals' Cash & Current Investments (Quarter) stood at $96.1 million in 2021, then soared by 260.96% to $346.9 million in 2022, then increased by 7.04% to $371.4 million in 2023, then crashed by 52.47% to $176.5 million in 2024, then surged by 94.89% to $344.0 million in 2025.
- Its last three reported values are $344.0 million in Q3 2025, $180.8 million for Q2 2025, and $204.1 million during Q1 2025.